These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15821508)

  • 21. Stone forming risk of calcium citrate supplementation in healthy postmenopausal women.
    Sakhaee K; Poindexter JR; Griffith CS; Pak CY
    J Urol; 2004 Sep; 172(3):958-61. PubMed ID: 15311008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Who makes uric acid stones and why--observations from a renal stones clinic.
    Stansbridge EM; Griffin DG; Walker V
    J Clin Pathol; 2013 May; 66(5):426-31. PubMed ID: 23454727
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The influence of uric acid on the calcium oxalate stone formation (author's transl)].
    Matouschek E; Huber R
    Urologe A; 1979 Jul; 18(4):211-4. PubMed ID: 38552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones.
    Goldfarb DS; MacDonald PA; Gunawardhana L; Chefo S; McLean L
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1960-7. PubMed ID: 23929928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of metabolic parameters between pure-uric acid and mixed-uric acid kidney stone formers.
    Ricapito A; Gupta K; Zipkin J; Yim S; Connors C; Khargi R; Yaghoubian AJ; Khusid JA; Atallah WM; Gupta M
    World J Urol; 2024 Mar; 42(1):138. PubMed ID: 38478092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in urinary stone risk factors in hypocitraturic calcium oxalate stone formers treated with dietary sodium supplementation.
    Stoller ML; Chi T; Eisner BH; Shami G; Gentle DL
    J Urol; 2009 Mar; 181(3):1140-4. PubMed ID: 19152919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elucidation of factors determining formation of calcium phosphate stones.
    Pak CY; Adams-Huet B
    J Urol; 2004 Dec; 172(6 Pt 1):2267-70. PubMed ID: 15538246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic abnormalities associated with calyceal diverticular stones.
    Auge BK; Maloney ME; Mathias BJ; Pietrow PK; Preminger GM
    BJU Int; 2006 May; 97(5):1053-6. PubMed ID: 16643491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urate and calcium oxalate stones: from repute to rhetoric to reality.
    Grover PK; Ryall RL
    Miner Electrolyte Metab; 1994; 20(6):361-70. PubMed ID: 7783698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin resistance and low urinary citrate excretion in calcium stone formers.
    Cupisti A; Meola M; D'Alessandro C; Bernabini G; Pasquali E; Carpi A; Barsotti G
    Biomed Pharmacother; 2007 Jan; 61(1):86-90. PubMed ID: 17184967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uric acid: an abettor or protector in calcium oxalate urolithiasis? Biochemical study in stone formers.
    Srinivasan S; Kalaiselvi P; Sakthivel R; Pragasam V; Muthu V; Varalakshmi P
    Clin Chim Acta; 2005 Mar; 353(1-2):45-51. PubMed ID: 15698589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Uric acid excretion in children with urolithiasis.
    Miller LA; Noe HN; Stapleton FB
    J Pediatr; 1989 Dec; 115(6):923-6. PubMed ID: 2585228
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urinary excretion of uricine.
    Pinto B; Rocha E
    Invest Urol; 1977 Sep; 15(2):155-7. PubMed ID: 20424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of overweight and obesity in calcium oxalate stone formation.
    Siener R; Glatz S; Nicolay C; Hesse A
    Obes Res; 2004 Jan; 12(1):106-13. PubMed ID: 14742848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and metabolic evaluation of Korean patients with urolithiasis.
    Park KJ; Jeon SS; Han DH; Lee SY
    Scand J Clin Lab Invest; 2011 Oct; 71(6):481-5. PubMed ID: 21714706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of renal stone risk by potassium-magnesium citrate during 5 weeks of bed rest.
    Zerwekh JE; Odvina CV; Wuermser LA; Pak CY
    J Urol; 2007 Jun; 177(6):2179-84. PubMed ID: 17509313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Dietary control for out-patients in urinary stone clinic].
    Kato T; Yanagawa M; Hioki T; Sakurai M; Yamakawa K; Araki T; Yamamoto I; Arima K; Tochigi H; Kawamura J
    Hinyokika Kiyo; 1993 Jul; 39(7):593-8. PubMed ID: 8362676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is idiopathic recurrent calcium urolithiasis in males a cellular disease? Laboratory findings in plasma, urine and erythrocytes, emphasizing the absence and presence of stones, oxidative and mineral metabolism: an observational study.
    Schwille PO; Manoharan M; Schmiedl A
    Clin Chem Lab Med; 2005; 43(6):590-600. PubMed ID: 16006254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idiopathic uric acid lithiasis: epidemiologic and metabolic aspects.
    Zechner O; Pflüger H; Scheiber V
    J Urol; 1982 Dec; 128(6):1219-23. PubMed ID: 7154174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.